达仁堂上半年净利19.28亿元，同比增长193.08%

Core Insights - The company reported a significant decline in revenue for the first half of 2025, with total operating income of 2.651 billion yuan, representing a year-on-year decrease of 33.15% [1] - Despite the drop in revenue, the net profit attributable to shareholders saw a substantial increase of 193.08%, amounting to 1.928 billion yuan [1] - The increase in net profit is primarily attributed to the after-tax gain of 1.308 billion yuan from the transfer of a 12% stake in China Medical Tianjin Schering Pharmaceutical Co., Ltd. [1] Financial Performance - Operating income for the first half of 2025: 2.651 billion yuan, down 33.15% year-on-year [1] - Net profit attributable to shareholders: 1.928 billion yuan, up 193.08% year-on-year [1] - After-tax gain from stake transfer: 1.308 billion yuan [1]